165 related articles for article (PubMed ID: 28083618)
21. [Association of CRBN Gene with Immunomodulatory Drug Resis- tance in Multiple Myeloma].
Cai QQ; Li J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Jun; 23(3):892-7. PubMed ID: 26117057
[TBL] [Abstract][Full Text] [Related]
22. Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using cereblon replacement, inhibition of STAT3 or targeting of IRF4.
Zhu YX; Shi CX; Bruins LA; Wang X; Riggs DL; Porter B; Ahmann JM; de Campos CB; Braggio E; Bergsagel PL; Stewart AK
Blood Cancer J; 2019 Feb; 9(2):19. PubMed ID: 30741931
[TBL] [Abstract][Full Text] [Related]
23. Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response.
Lopez-Girona A; Heintel D; Zhang LH; Mendy D; Gaidarova S; Brady H; Bartlett JB; Schafer PH; Schreder M; Bolomsky A; Hilgarth B; Zojer N; Gisslinger H; Ludwig H; Daniel T; Jäger U; Chopra R
Br J Haematol; 2011 Aug; 154(3):325-36. PubMed ID: 21707574
[TBL] [Abstract][Full Text] [Related]
24. A novel effect of thalidomide and its analogs: suppression of cereblon ubiquitination enhances ubiquitin ligase function.
Liu Y; Huang X; He X; Zhou Y; Jiang X; Chen-Kiang S; Jaffrey SR; Xu G
FASEB J; 2015 Dec; 29(12):4829-39. PubMed ID: 26231201
[TBL] [Abstract][Full Text] [Related]
25. The molecular mechanism of thalidomide analogs in hematologic malignancies.
Lindner S; Krönke J
J Mol Med (Berl); 2016 Dec; 94(12):1327-1334. PubMed ID: 27492707
[TBL] [Abstract][Full Text] [Related]
26. IMiDs: Not for the CRBN weak.
Pearse RN
Leuk Res; 2014 Jan; 38(1):21-2. PubMed ID: 24239176
[No Abstract] [Full Text] [Related]
27. [Cereblon - a new target of therapy in the treatment of multiple myeloma].
Staňková M; Bešše L; Sedlaříková L; Vrábel D; Hájek R; Sevčíková S
Klin Onkol; 2014; 27(5):326-30. PubMed ID: 25312709
[TBL] [Abstract][Full Text] [Related]
28. Association of interferon regulatory factor 4 gene polymorphisms rs12203592 and rs872071 with skin cancer and haematological malignancies susceptibility: a meta-analysis of 19 case-control studies.
Wang S; Yan Q; Chen P; Zhao P; Gu A
BMC Cancer; 2014 Jun; 14():410. PubMed ID: 24906573
[TBL] [Abstract][Full Text] [Related]
29. [Advances of CRBN in Immunomodulatory Drugs for Multiple Myeloma-Review].
An R; Hou J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Dec; 24(6):1888-1891. PubMed ID: 28024514
[TBL] [Abstract][Full Text] [Related]
30. Expression of the cereblon binding protein argonaute 2 plays an important role for multiple myeloma cell growth and survival.
Xu Q; Hou YX; Langlais P; Erickson P; Zhu J; Shi CX; Luo M; Zhu Y; Xu Y; Mandarino LJ; Stewart K; Chang XB
BMC Cancer; 2016 May; 16():297. PubMed ID: 27142104
[TBL] [Abstract][Full Text] [Related]
31. Regulatory network of BLIMP1, IRF4, and XBP1 triad in plasmacytic differentiation and multiple myeloma pathogenesis.
Tang TF; Chan YT; Cheong HC; Cheok YY; Anuar NA; Looi CY; Gan GG; Wong WF
Cell Immunol; 2022 Oct; 380():104594. PubMed ID: 36081178
[TBL] [Abstract][Full Text] [Related]
32. IRF4 rs12203592 functional variant and melanoma survival.
Potrony M; Rebollo-Morell A; Giménez-Xavier P; Zimmer L; Puig-Butille JA; Tell-Marti G; Sucker A; Badenas C; Carrera C; Malvehy J; Schadendorf D; Puig S
Int J Cancer; 2017 Apr; 140(8):1845-1849. PubMed ID: 28103633
[TBL] [Abstract][Full Text] [Related]
33. Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors.
Gopalakrishnan R; Matta H; Tolani B; Triche T; Chaudhary PM
Oncogene; 2016 Apr; 35(14):1797-810. PubMed ID: 26119939
[TBL] [Abstract][Full Text] [Related]
34. MMSET regulates expression of IRF4 in t(4;14) myeloma and its silencing potentiates the effect of bortezomib.
Xie Z; Bi C; Chooi JY; Chan ZL; Mustafa N; Chng WJ
Leukemia; 2015 Dec; 29(12):2347-54. PubMed ID: 26196464
[TBL] [Abstract][Full Text] [Related]
35.
Wróbel T; Butrym A; Łacina P; Rybka J; Gębura K; Mazur G; Bogunia-Kubik K
Anticancer Res; 2017 Apr; 37(4):1799-1803. PubMed ID: 28373444
[TBL] [Abstract][Full Text] [Related]
36. IKZF1 expression is a prognostic marker in newly diagnosed standard-risk multiple myeloma treated with lenalidomide and intensive chemotherapy: a study of the German Myeloma Study Group (DSMM).
Krönke J; Kuchenbauer F; Kull M; Teleanu V; Bullinger L; Bunjes D; Greiner A; Kolmus S; Köpff S; Schreder M; Mügge LO; Straka C; Engelhardt M; Döhner H; Einsele H; Bassermann F; Bargou R; Knop S; Langer C
Leukemia; 2017 Jun; 31(6):1363-1367. PubMed ID: 28017969
[TBL] [Abstract][Full Text] [Related]
37. Relationship between interferon regulatory factor 4 genetic polymorphisms, measures of sun sensitivity and risk for non-Hodgkin lymphoma.
Gathany AH; Hartge P; Davis S; Cerhan JR; Severson RK; Cozen W; Rothman N; Chanock SJ; Wang SS
Cancer Causes Control; 2009 Oct; 20(8):1291-302. PubMed ID: 19396635
[TBL] [Abstract][Full Text] [Related]
38. Multiple myeloma risk variant at 7p15.3 creates an IRF4-binding site and interferes with CDCA7L expression.
Li N; Johnson DC; Weinhold N; Studd JB; Orlando G; Mirabella F; Mitchell JS; Meissner T; Kaiser M; Goldschmidt H; Hemminki K; Morgan GJ; Houlston RS
Nat Commun; 2016 Nov; 7():13656. PubMed ID: 27882933
[TBL] [Abstract][Full Text] [Related]
39. A polymorphism in the 3' UTR of IRF4 linked to susceptibility and pathogenesis in chronic lymphocytic leukaemia and Hodgkin lymphoma has limited impact in multiple myeloma.
Pratt G; Fenton JA; Allsup D; Fegan C; Morgan GJ; Jackson G; Sunter NJ; Hall AG; Irving JA; Allan JM
Br J Haematol; 2010 Aug; 150(3):371-3. PubMed ID: 20408839
[No Abstract] [Full Text] [Related]
40. Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4.
Bjorklund CC; Lu L; Kang J; Hagner PR; Havens CG; Amatangelo M; Wang M; Ren Y; Couto S; Breider M; Ning Y; Gandhi AK; Daniel TO; Chopra R; Klippel A; Thakurta AG
Blood Cancer J; 2015 Oct; 5(10):e354. PubMed ID: 26430725
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]